Multidimensional prognostic indices for use in COPD patient care. A systematic review by van Dijk, Wouter D et al.
REVIEW Open Access
Multidimensional prognostic indices for use in
COPD patient care. A systematic review
Wouter D van Dijk
1*, Lisette van den Bemt
1, Saskia van den Haak-Rongen
2, Erik Bischoff
1, Chris van Weel
1,
Johannes CCM in ‘t Veen
3 and Tjard RJ Schermer
1
Abstract
Background: A growing number of prognostic indices for chronic obstructive pulmonary disease (COPD) is
developed for clinical use. Our aim is to identify, summarize and compare all published prognostic COPD indices,
and to discuss their performance, usefulness and implementation in daily practice.
Methods: We performed a systematic literature search in both Pubmed and Embase up to September 2010.
Selection criteria included primary publications of indices developed for stable COPD patients, that predict future
outcome by a multidimensional scoring system, developed for and validated with COPD patients only. Two
reviewers independently assessed the index quality using a structured screening form for systematically scoring
prognostic studies.
Results: Of 7,028 articles screened, 13 studies comprising 15 indices were included. Only 1 index had been
explored for its application in daily practice. We observed 21 different predictors and 7 prognostic outcomes, the
latter reflecting mortality, hospitalization and exacerbation. Consistent strong predictors were FEV1 percentage
predicted, age and dyspnoea. The quality of the studies underlying the indices varied between fairly poor and
good. Statistical methods to assess the predictive abilities of the indices were heterogenic. They generally revealed
moderate to good discrimination, when measured. Limitations: We focused on prognostic indices for stable disease
only and, inevitably, quality judgment was prone to subjectivity.
Conclusions: We identified 15 prognostic COPD indices. Although the prognostic performance of some of the
indices has been validated, they all lack sufficient evidence for implementation. Whether or not the use of
prognostic indices improves COPD disease management or patients’ health is currently unknown; impact studies
are required to establish this.
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Background
Chronic obstructive pulmonary disease (COPD) is a
chronic respiratory condition, with a high impact on
patients’ wellbeing, health care utilization, and mortality
[1]. The (progressive) airflow obstruction that is charac-
teristic for COPD is closely related to its morbidity and
mortality [1-3]. Hence, degree of airflow obstruction is
generally considered to be the key factor for staging
COPD severity and to guide and monitor treatment [1].
However, (pharmacological) interventions to both
stabilize the progression of airflow obstruction and
reduce premature mortality are disappointing [4-6]. Cur-
rently, there is a growing recognition that COPD should
no longer be regarded as a synonym for airflow obstruc-
tion alone, but instead as a multidimensional condition
that comprises several phenotypes [1,7-10]. In addition,
patients tend to die from other diseases than COPD [11].
Therefore, severity staging and treatment of COPD
should follow this view and take into account the hetero-
genic nature of the disease.
Apart from airflow obstruction, a range of other factors
have been identified as important predictors of future
risk on morbidity and mortality in patients with COPD,
including smoking [12,13], degree of dyspnoea [14], age
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any medium, provided the original work is properly cited.[15], exercise capacity [16], body mass index [17], exacer-
bations [18], (cardiovascular) comorbidity [19], and qual-
ity of life [20]. Combining several of these prognostic
factors in a multidimensional index embodies the current
holistic vision on COPD, and may ultimately provide
physicians with a powerful tool to assess and monitor
disease severity in order to guide decision making and
improve patient outcome [9,21]. Such an index clearly
needs to meet several prerequisites in terms of accuracy,
predictive and discriminative power, internal and exter-
nal validity and, last but not least, practicability of use in
different health care settings [22,23]. In addition to moni-
toring and guiding decision making in patients, a prog-
nostic index could also be used to predict patients’ health
care utilization, to identify and target particular high-risk
groups within the COPD patient population, or for risk
stratification in clinical trials.
With the growing number of prognostic COPD indices
developed for clinical use, an overview to facilitate the dis-
cussion of the pros and cons of using prognostic indices in
COPD patient care is warranted. In this paper, we aim to
identify, summarize and compare all published multidi-
mensional prognostic indices that assess and stage disease
severity in patients with COPD. Apart from providing
insight in their performance, we aim to present the effects
of their application in daily patient care, that will be
important to help clinicians, scientists and health policy
makers in deciding whether or not to implement an index.
Methods
We performed a systematic literature review on multidi-
mensional prognostic indices for COPD.
Literature search
We comprehensively traced indices by systematically
searching the Pubmed and Embase literature databases
(see Additional File 1 and 2 for search strategies). We con-
ducted the Pubmed search first and included all records
published before 27 September 2010. The Pubmed search
was not restricted to language. As the first index traced in
Pubmed was published in 2004, the subsequent Embase
search was limited to records published after 2002, and to
records in English, German, French or Dutch. Two
authors (LvdB and TS) independently screened the titles
and abstracts of the retrieved records to identify poten-
tially eligible studies, and next assessed eligibility by full-
text assessment. Disagreement was resolved by consensus,
and if necessary by a third party (SvdH). In addition, we
searched the bibliographies of included articles for relevant
cross-references and searched Pubmed and Embase for
index-related articles reporting supplementary information
on validity, usefulness, and/or additional prognostic
outcomes.
Study selection
We included primary publications of prognostic indices
that: 1) were developed specifically for COPD; 2) were
developed and validated in samples with COPD patients
only; 3) were developed for assessment of COPD patients
with stable disease (i.e., not during exacerbations or hos-
pitalizations); 4) predict future outcome of COPD; 5)
consist of more than one component; 6) have a scoring
system for their components. As the quality of the prog-
nostic indices was part of our evaluation we did not
exclude indices based on poor quality.
Data extraction and quality assessment
The following data were extra c t e df r o me a c hi n c l u d e d
study: age, gender, and airflow obstruction as measured by
FEV1/FVC (forced expiratory volume in one second/forced
vital capacity), FEV1%( F E V 1 as percentage of the pre-
dicted value), and index purposes, predictors, prognostic
outcomes and prognostic value. Ideally, a prognostic index
progresses through three consecutive stages: development,
validation, and impact quantification. There is no consen-
sus on the ‘best’ method for development. Indices can be
build from a set of predefined predictors that may either
be established predictors and/or be selected based on
practicability of measuring the predictor. The predictors
could be selected based on their availability and pragma-
tism or by statistical modeling. The subsequent perfor-
mance and validity of the developed index should be
measured by its discriminative properties: how well does
the index distinguish patients with poor prognosis from
patients with good prognosis (c-statistic 0.50 equals ran-
dom guessing, > 0.70 is good performance, 1.0 is maxi-
mum), and by its accuracy (how well do predictions from
the index measures up to the real observations, i.e. ‘good-
ness-of-fit’). Since not all studies that report prognostic
indices for COPD included this information in their meth-
ods, we additionally extracted data on correlation, multiple
regression and survival analyses. To conclude the valida-
tion stage, an index should be investigated in a separate
validation cohort in order to test generalization and, if
applicable, it should be compared with conventional prog-
nostic measures (in the case of COPD with FEV1%. In gen-
eral, if based on statistical selection of predictors and in
smaller samples, the index is likely to perform better in its
primary cohort. Before implementing an index in daily
practice, the final challenge is to assess the effects on
patient outcome and health care by impact studies [21-23].
WvD and LvdB independently scored the methodologi-
cal quality of the studies using a structured screening form
(Additional File 3), that exposes potential systematic bias
and the validity of the generated indices: from good to
poor, based on the average score of 6 items. This form
was derived from a framework specifically developed for
van Dijk et al. Respiratory Research 2011, 12:151
http://respiratory-research.com/content/12/1/151
Page 2 of 11the evaluation of the methodological quality of prognosis
studies in systematic reviews by Hayden et al, who
extracted and grouped all quality items from 163 prognos-
tic reviews [24].
Results
Study selection
F i g u r e1s u m m a r i z e st h es e l e c t i o no fs t u d i e s .O ft h e
7,028 identified records, 31 were assessed for eligibility.
After full-text assessment, we excluded 18 articles
because of a lack of a scoring system for individual
patients [25-27], absence of prognostic outcome [28-38],
not being the original publication of an index [39-41],
and not being COPD specific [42]. Consequently, we
included 13 studies that altogether reported 15 multidi-
mensional COPD indices (Table 1 and Additional Files 3
and 4). The first index was published in 2004 [43],
whereas 2009 yields most studies. The prior purpose of
most studies was to develop or improve an index for clin-
ical use. Only 1 index was initially developed for epide-
miologic use [30]. Index modeling was based on either
achieving maximal predictive value or on practicability
and mostly used statistical selection of predictors.
Index descriptions
The indices were established from study samples that
ranged from 50 to 8802 patients, whereas their mean
follow-up ranged from 0.5 to 6.1 years. The weighted
average of FEV1% was 44% (study means range 35 to
63%). We observed large variation in predictors, scoring
systems and outcomes (Table 1 and Additional File 4).
From all indices, 21 predictors (Table 2) emerged for 7
different outcomes (Table 3). Across indices, shared pre-
dictors were often measured with different instruments,
variously categorized, and diversely valued and weighted.
For instance, 4 instruments were used to measure dys-
pnoea and 6 categorizations were applied to stage
FEV1% (Additional File 4). Two of these categories
deviated from the guidelines they referred to [43,44], i.e.
the cut-point of 65% was not mentioned in those guide-
lines [45,46]. Altogether, the indices included 3 to 8 pre-
dictors and their maximum scoring ranged from 8 to
422 points. Airflow obstruction - expressed as FEV1%-
was included in all indices except for one [47]. Other
frequently included predictors were age, dyspnoea, exer-
cise tolerance and Body Mass Index (BMI).
Mortality, as defined by all-cause or respiratory cause,
was the most frequent predicted outcome (n = 8)
[15,43,44,48-51], followed by all-cause or respiratory hos-
pitalization (n = 4) [47,48,52,53], exacerbation (n = 4)
[48,52-54], and unscheduled in- and outpatient visits (n =
1) [47]. Correlation with another index [43] was the only
outcome in one study [55]. One study combined respira-
tory death and hospitalization as a composite outcome
G
G
G
G
G
G
G
GG
G
3417 records identified 
through Pubmed 
4574 records identified 
through Embase 
7028 records 
screened 
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Figure 1 PRISMA Flow Diagram. * Three articles excluded based on lack of scoring system, 11 due to absence of prognostic outcome, 3 were
not the original publication of the index, and 1 was not COPD specific.
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Page 3 of 11Table 1 Essential index summaries: general information, predictive ability, population and study quality.
INDEX GENERAL INDEX INFORMATION INDEX QUALITY POPULATION STUDY QUALITY KEY STRENGTHS/
FLAWS
Scale and
publication
year
Index
aim
Cited
(SCI)
Predictors Outcome Predictor
ind. Sig.
Discrimi
nation
Accu
racy
Compare
to
N Age
(year)
Mean
FEV1%
Score Model
building
Val.
cohort
ADO
10-points scale
2009
C 14 Age
Dyspnoea
(MRC or GCRQ)
Obstruction
(FEV1%)
Death Yes Modest Good BODE 232
342
72
68
52%
all <
80%
Fairly
good
A* + Accurate
Age is
paradoxical
Elderly patients
only
BODE
10-point scale
4 categories
2004
C 580 BMI (length/
weight
2)
Obstruction
(FEV1%)
Dyspnoea
(MRC score)
Exercise
tolerance
(6MWD)
Death
Respiratory death
Yes Death:
Good
Respiratory:
no report
- FEV1% 207
625
66
67
39-
47%
Good A* + Good quality
Good discrimination
Severe COPD only
Exclusion of CVD
➣ BODEx
9-point
scale
4
categories
2009
D 7 BMI (length/
weight
2)
Obstruction
(FEV1%)
Dyspnoea (MRC
score)
Exacerbations
Death All but 1 Good - BODE 185 71 48% Fair P - Good discrimination
Elderly males
only
➣ e-BODE
12-point
scale
4
categories
2009
D 7 Exacerbations
BMI (length/
weight
2)
Obstruction
(FEV1%)
Dyspnoea (MRC
score)
Exercise
tolerance
(6MWD)
Death All but 1 Good - BODE 185 71 48% Fair A - Good discrimination
Elderly males
only
➣ mBODE
10-point
scale
2007
D 3 BMI (length/
weight
2)
Obstruction
(FEV1%)
Dyspnoea (MRC
score)
Exercise max.
O2-use
Correlation BODE - - - BODE 50 63 63% Fair A - Small sample
Restricted
outcome and
analysis
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1Table 1 Essential index summaries: general information, predictive ability, population and study quality. (Continued)
COPDSS:
COPD
Severity
Score
35-point scale
2008
E 7 Respiratory
symptoms
Systemic
corticosteroids
Other COPD
medications
Hospitalization/
Intubation
Home oxygen
use
Respiratory outpatient
Respiratory ED visit
Respiratory hospital
-
(index
yes)
- - - 267 65 54% Fair P ±
$ Nomogram
Diagnosis based
on self-report
No outcome
confirmation
CPI: COPD
Prognostic
Index
100-point
scale
3 categories
2008
C 2 Quality of life
(SGRQ/CRQ)
Obstruction
(FEV1%)
Age
Gender
BMI
History of ED/
exacerbation
History of CVD
Death
Hospitalization
Exacerbation
Depends
on
outcome
Model:
Good
Val.cohort:
no report
- - 5856
2946
64
64
44% Fairly
poor
P* + Adequate statistics
Large sample
Selective
reporting
Pooled analysis
DOREMI BOX
10-point scale
2 categories
2008
D ? Dyspnoea
(ATS)
Obstruction
(FEV1%)
Rate of
Exacerbation
Movement
(6MWD)
BMI (length/
weight
2)
Blood OXygen
(PaO2)
Correlation BODE
Death
Yes
(2 no
report)
- - BODE 84 59 35%
(18-
73%)
Fairly
good
A- Clear descriptions
Long follow-up
Small sample
Limited statistics
Severe
population
DOSE,
8-point scale
2009
C 3 Dyspnoea
(MRC score)
Obstruction
(FEV1%)
Smoking
Exacerbations
Correlation BODE
Exacerbation
Hospitalization for
exacerbation
-
(index
partly)
Hospital
Good
Exacerbation
no report
- BODE 375
81
133
69
73
67
42-
67%
all <
80%
Fairly
poor
P* +
# Difficult, complex
and selective
reporting
Violated own
protocol
HADO
12-point scale
3 categories
2006
C 5 Health (new
questionnaire)
Activity (new
questionnaire)
Dyspnoea
(Fletcher)
Obstruction
(FEV1%)
Death No Modest - FEV1% 611 67 50%
all <
80%
Fairly
good
P- Clear descriptions
Compared to FEV1%
Modest
discrimination
Predictors
debatable
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1Table 1 Essential index summaries: general information, predictive ability, population and study quality. (Continued)
Niewoehner
(1)
422-point
scale
2007
C 27 Age
Obstruction
(FEV1%)
Hospitalization
COPD duration
Productive
cough
Antibiotics
Systemic
corticosteroids
Theophylline
Exacerbation Yes Modest Seems
good
@
- 1829 69 36%
all <
60%
Fair A* - Large sample
No validation
cohort
Severe COPD/
males only
No outcome
confirmation
Niewoehner
(2)
249-point
scale
2007
C 27 Age
Obstruction
(FEV1%)
Hospitalization
Unscheduled
visits
Cardiovascular
disease
Oral
corticosteroids
Hospitalization for
exacerbation
Yes Good Seems
good
@
- 1829 69 36%
all <
60%
Fair A* - Good discrimination
Large sample
No validation
cohort
Severe COPD/
males only
No outcome
confirmation
Predictor is
outcome
PILE 2010
10-point scale
4 categories
C 0 Obstruction
(FEV1%)
Interleukin-6
Knee extensor
strength
Death Yes Good - FEV1%
mBODE
268 73 63%
all >
30%
Fair A* - Long follow-up
Good statistics
No validation
cohort
SAFE 2007
9-point scale
4 categories
C 5 SGRQ score
(questionnaire)
Air-flow
limitation
(FEV1%)
Exercise
tolerance
(6MWD)
Exacerbation
(correlation)
- - - - 86 68 43%
(12-
98%)
Fair P - Small sample
Poor statistics
Schembri
(TARDIS)
16-point scale
2009
C 0 Age
BMI
Dyspnoea
(MRC score)
Obstruction
(FEV1%)
Hospitalization
Influenza
vaccination
Hospitalization for COPD
or respiratory death as 1
outcome
Yes - - - 3343 ? ?
all <
80%
Fair to
fairly
poor
A* - Large sample
No validation
cohort
Composite
outcome
Limited statistics
Indices are sorted alphabetically. Index aim: primary purpose of utilization: C) clinical use, D) further development of existing index, E) epidemiologic use; Score: average of bias screening form; Model building:
priorities in model development (* if predictors are statistically selected): A) accuracy, P) pragmatism; Val. cohort: separate validation cohort; SCI: science citation index; Predictor ind. sig.: independent significance of
predictors for outcome; $: same cohort, different time-window; #: Selective use and reporting of cohorts;
@: reliability plot without statistics. CVD: cardiovascular disease
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1[56]. Two studies also analyzed the change of the index
over time and the association with outcome [47,52]. Defi-
nitions and methods of measurement of shared outcomes
varied across indices, particularly for exacerbations (Addi-
tional File 3).
Performance and quality
Table 1 reveals the statistical methods used to validate
the performance of the respective indices, which were
heterogenic and often deficient. Only 3 indices were
compared to FEV1% and showed a modest, not formally
tested, improvement of discriminative power in contrast
to FEV1% (c-statistics increased from 0.63 - 0.65 to 0.68
-0 . 7 4 ) .O n l y5s t u d i e su s e ds o m es o r to fv a l i d a t i o n
cohort. Apart from these primary studies, only 2 indices
had been additionally validated for their outcomes in
succeeding studies [43,55], whereas 3 indices had been
additionally evaluated for other outcomes (Additional
File 4) [43,48,55]. Remarkably, we retrieved only 1 (non-
controlled pilot) impact study that implemented a multi-
dimensional prognostic index in COPD patient care (11
patients included, 6 months follow-up, no significant
improvements due to case management directed by the
index) [57].
The overall methodological quality varied from fairly
poor to good (Table 1). All studies described the base-
line characteristics of their sample adequately, but only
half described their process of patient recruitment and
selection. Nine studies did not properly report the study
attrition, information on drop-outs in particular, and
one study appeared to violate its own protocol for pre-
dictor selection [52]. Measurements sometimes
remained undefined and were inadequate for several
indices, in particular with respect to (lack of) outcome
confirmation.
Discussion
We identified 15 different multidimensional prognostic
COPD indices, of which several have been validated
appropriately. Although most indices were developed for
clinical use, as yet, these indices lack impact studies to
demonstrate effects on patient outcome and health care
Table 2 COPD outcome predictors (n = 21), grouped by disease components
COMPONENT PREDICTOR N
Physiologic - Obstruction (FEV1 as % from predicted) 14
- Blood oxygen (PaO2) 1
- Exercise maximum oxygen consumption 1
Biomarkers - Interleukin-6 1
Physical - BMI (length/weight2) 7
- Exercise tolerance (6MWD) 4
- Knee extensor strength 1
Medical history - COPD duration 1
- (Rate of) exacerbation (unscheduled visits, emergency department visits, hospitalisation, intubation) 8
- History of cardiovascular disease 2
Demographics - Age 5
- Gender 1
- Smoking status 1
- Influenza vaccination status 1
Signs & symptoms - Dyspnoea (ATS, MRC score, GCRQ, and Fletcher) 9
- Quality of life (SGRQ) 2
- Health status (CRQ and ad hoc questionnaires) 2
- Respiratory symptoms like cough 2
Treatment - COPD medication (including steroids and theophylline) 3
- Antibiotics 1
- Home oxygen 1
N is number of indices.
Table 3 Summary of different outcomes used in
prognostic COPD indexes
OUTCOME SPECIFIC INDEX OUTCOME N
Death - All-cause death 8
- Respiratory death 2*
Hospitalisation - All-cause hospitalization 1
- Respiratory hospitalization 4*
Exacerbation - Unscheduled respiratory outpatient visit 1
- Respiratory emergency department visit 1
- Any exacerbation 4
N is number of studies. * One study used these outcomes as a composite
outcome
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may improve population-based prediction of the natural
course of COPD compared to looking at airway obstruc-
tion (as measured by FEV1%) alone, in terms of mortal-
ity, hospitalizations and exacerbations, although
discrimination still remains modest. The diversity in
populations, (the weighting of) predictors and (the defi-
nition of) outcome, hampers any overall recommenda-
tions on which index to prefer for predicting prognosis
in patients with COPD. However, our overview of the
indices currently available can guide future research in
selecting the most suitable index/indices for impact
studies.
Strengths and limitations
Our systematic search in two leading medical literature
databases limited the chance of missing an index. The
Embase search did not reveal additional indices. As there
is no consensus on how to perform quality assessment of
studies in systematic reviews of prognostic studies, we
based our study assessments on Hayden’sp r e v i o u s l y
reported criteria, in an effort to enhance (the validity of)
our study evaluations [24]. A limitation of our review is
the (inevitable) subjectivity when judging the methodolo-
gical quality of the studies underlying the indices, includ-
ing deficient blinding of the studies. We attempted to
counteract subjectivity by independent and systematic
scoring by two investigators. Finally, we focused on prog-
nostic indices for stable disease only and excluded indices
that had been developed for acute exacerbations, or that
assessed current disease severity only without predicting
future outcome(s).
Interpretation
Although the quality of the studies generally appeared
fair, the lack of proper analyses on their predictive per-
formance and the lack of uniformity across indices ham-
pers any recommendations regarding preference for any
particular index. Altogether, rather than truly improving
predictive abilities, the large number of COPD indices
mainly substantiate the important value of airflow
obstruction on population level. Although regarded as a
relatively difficult and impractical measurement to
obtain, this single predictor is required for the diagnosis
of COPD [1]. Most other predictors would be relatively
easy to perform, except for time and space consuming
exercise tests, of which age and dyspnoea in particular
seem reliable and predictive measures.
As smoking is an important, easily measured and modi-
fiable predictor of COPD prognosis, we were surprised to
observe that of 6 studies that reported smoking, only 1
(fairly poor) study included smoking in its index. Seven
studies did not have information about smoking avail-
able. Obviously, smoking status and smoking intensity
may change repeatedly over time and self-reported relia-
bility is poor, requiring confirmation tests like urine ana-
lyses. Furthermore, age is an excellent predictor in both
cardiovascular and COPD indices [58]. However, age
seems a difficult predictor to value in a prognostic index
for secondary prevention, such as with COPD [59]. Age
is non-modifiable and its usefulness in tailoring indivi-
dual COPD treatment accordingly is less obvious: it may
prohibit treatment of young patients, and younger
patients would ironically have less urgency to quit
smoking.
Although the COPD indices could be used for epidemio-
logic and research purposes, they would ideally support
(cost-effective) decision making on individual treatment in
order to improve outcome in patients with COPD [9,21],
or even as to provide individual prognoses. So far, only
one (pilot) study actually implemented a prognostic
COPD index in patient care, without showing significant
improvements in health (care) [57]. As the practical abil-
ities of COPD indices remain unexposed, they fail to tackle
the current urge to improve treatment programs [7,9,60].
Ongoing research by prospective follow-up of a wide
range of (known and new) predictors specifically aims to
further improve both phenotyping and the prognostic
capacity of COPD indices [61,62]. However, as the ‘proof
of the pudding’ would be to actually study the effect of
applying such an index in directing decision making and
outcome in individual patients, research priorities would
need to shift towards these objectives, preferably by means
of impact studies [9,21,23]. Different indices might prove
to be suitable for different populations, purposes and set-
tings [63]. Although impact studies have not (yet) been
used commonly for prognostic indices [23], we believe
that COPD treatments with variable effects further urge to
study the effects of implementing an index in daily
practice.
Recommendations
Following the development and validation of the current
indices, the next step for COPD researchers is to perform
impact studies, instead of developing more indices [23].
These studies should establish both the applicability and
the impact on health(care) of implementation of these
indices in daily clinical practice. An impact study requires
a randomized controlled trial that quantifies the effect of
using a prognostic index on predefined outcomes includ-
ing decision making, patient outcome, and cost effective-
ness, compared with usual care without implementing
the index [23].
Another issue is whether or not a prognostic index
should integrate predictors, preferably modifiable [9], of
which treatments can indeed improve the index scores and
outcome [64,65]. Ultimately, indices should be integrated
with predictive, preventive, personalized and participatory
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strategies for individual COPD phenotypes. To improve
applicability in clinical practice, a 5
th P could be added for
‘practical’.
Finally, applying a prognostic index in a patient popula-
tion other than the one in which it was developed may
require recalibration or modification. For example, Puhan
et al. recently reported improved prognostic performance
of the BODE index after population-based recalibration
[15]. Age-specific calibration or stratification of an index
allows adjustments that can resolve the dilemma of this
strong but troublesome predictor [58]. Apart from age,
calibration to critically-ill patients in need of (decisions on
their) ICU admission and/or ventilation, might prove its
benefit. In addition, this population could also benefit
from non-modifiable predictors that merely define a high-
risk group of patients [67].
Conclusions
We identified 15 multidimensional prognostic indices spe-
cifically developed for COPD patients. Although the over-
all prognostic performance appears moderate to good and
several indices have been validated, there currently is a
lack of evidence that prognostic indices improve decision
making, treatment or outcome in patients with COPD.
The next challenge is to perform impact studies that
determine if implementation of specific indices can indeed
improve individual health(care) in specific settings.
Additional material
Additional file 1: Pubmed Database Search: Pubmed Search strategy.
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Additional file 4: Detailed Index Summaries: Contains a more
extensive summary of the index characteristics and properties.
Acknowledgements
The principal investigator (WvD) had full access to all of the data in the
study and takes responsibility for the integrity of the data and the accuracy
of the data analysis.
Funding: The paper was supported by a university grant (RvB08.066.51196/
GE) by Radboud University Nijmegen Medical Center, Nijmegen, the
Netherlands, which has no interference with the study with regards to
design, data collection, analyses, manuscript submission or whatsoever.
We wish to thank Ms. Elmie Peters for her advice in the literature search.
Author details
1Radboud University Nijmegen Medical Centre, Department of Primary and
Community Care, Nijmegen, the Netherlands.
2QUARTZ Integrated Care
Support Service, Helmond, the Netherlands.
3Sint Franciscus Gasthuis,
Department of Chest Diseases, Rotterdam, the Netherlands.
Authors’ contributions
All authors read and approved the final manuscript. WvD: Acquisition and
interpretation of data, drafting of the manuscript. LvdB: Study concept and
design, acquisition and interpretation of data, drafting of the manuscript.
SvdH: Drafting of the manuscript. EB: Drafting of the manuscript. CvW:
Drafting and critical revision of the manuscript. JiV: Drafting and critical
revision of the manuscript. TS: Study concept, design and supervision,
acquisition and interpretation of data, drafting and critical revision of the
manuscript
Competing interests
There are no conflicts of interest of any kind related to this paper. Conflicts
of interest, not related to this paper: Johannes in ‘t Veen received fees for
consultancy or lectures from Astra Zeneca, Boehringer Ingelheim, Cheisi,
Novartis and Nycomed. Tjard Schermer received fees or grants for his
department used for research, education, equipment, salaries, etc. from
NutsOhra Fund, GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim.
Chris van Weel received unrestricted fees or grants for his department for
research, education, equipment, salaries, etc. from Bayer, NovoNordisk, Astra
Zeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. Wouter van
Dijk, Lisette van den Bemt, Erik Bischoff and Saskia van den Haak-Rongen do
not have any conflict of interest.
Received: 20 April 2011 Accepted: 14 November 2011
Published: 14 November 2011
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global
Strategy for Diagnosis, Management, and Prevention of COPD (2010).
[http://www.goldcopd.com].
2. Mannino DM, Reichert MM, Davis KJ: Lung function decline and outcomes
in an adult population. Am J Respir Crit Care Med 2006, 173(9):985-990.
3. Anthonisen NR, Wright EC, Hodgkin JE, IPPB Trial Group: Prognosis in
chronic obstructive pulmonary disease. Am Rev Respir Dis 1986, 133:14-20.
4. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A
4-year trial of tiotropium in chronic obstructive pulmonary disease. N
Engl J Med 2008, 359(15):1543-1554.
5. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ: Inhaled corticosteroids
for stable chronic obstructive pulmonary disease. Cochrane Database Syst
Rev 2007, , 2: CD002991.
6. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW,
Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in
chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
7. van den Bemt L, Schermer TRJ: Multicomponent staging indices for COPD
in daily patient care: what’s the yield? Int J Clin Pract 2010,
64(11):1475-1479.
8. Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence,
and future trends. Lancet 2007, 370(9589):765-773.
9. Schunemann H: From BODE to ADO to outcomes in multimorbid COPD
patients. Lancet 2009, 374(9691):667-668.
10. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM,
Goldin JG, Jones PW, MacNee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC,
Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic
obstructive pulmonary disease phenotypes: the future of COPD. Am J
Respir Crit Care Med 2010, 182(5):598-604.
11. Berry CE, Wise RA: Mortality in COPD: causes, risk factors, and prevention.
COPD 2010, 7(5):375-382.
12. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, Burns DM,
Prescott E, Vestbo J: COPD-related morbidity and mortality after smoking
cessation: status of the evidence. Eur Respir J 2008, 32(4):844-853.
13. Ezzati M, Lopez AD: Estimates of global mortality attributable to smoking
in 2000. Lancet 2003, 362(9387):847-852.
14. Nishimura K, Izumi T, Tsukino M, Oga T: Dyspnea is a better predictor of
5-year survival than airway obstruction in patients with COPD. Chest
2002, 121(5):1434-1440.
15. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, Agusti AG,
Gomez FP, Rodriguez-Roisin R, Moons KG, Kessels AG, Held U: Expansion of
the prognostic assessment of patients with chronic obstructive
pulmonary disease: the updated BODE index and the ADO index. Lancet
2009, 374(9691):704-711.
16. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T: Analysis of the factors
related to mortality in chronic obstructive pulmonary disease: role of
exercise capacity and health status. Am J Respir Crit Care Med 2003,
167(4):544-549.
van Dijk et al. Respiratory Research 2011, 12:151
http://respiratory-research.com/content/12/1/151
Page 9 of 1117. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP: Prognostic value of
nutritional status in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 1999, 160(6):1856-1861.
18. Donaldson GC, Wedzicha JA: COPD exacerbations 1: Epidemiology. Thorax
2006, 61(2):164-168.
19. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes
of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir
J 2008, 32(4):962-969.
20. Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD: Using quality of life to
predict hospitalization and mortality in patients with obstructive lung
diseases. Chest 2002, 122(2):429-436.
21. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG: Prognosis
and prognostic research: what why and how? BMJ 2009, 338:b375.
22. Altman DG, Vergouwe Y, Royston P, Moons KG: Prognosis and prognostic
research: validating a prognostic model. BMJ 2009, 338:b605.
23. Moons KG, Altman DG, Vergouwe Y, Royston P: Prognosis and prognostic
research: application and impact of prognostic models in clinical
practice. BMJ 2009, 338:b606.
24. Hayden JA, Cote P, Bombardier C: Evaluation of the quality of prognosis
studies in systematic reviews. Ann Intern Med 2006, 144(6):427-437.
25. Fan VS, Ramsey SD, Make BJ, Martinez FJ: Physiologic variables and
functional status independently predict COPD hospitalizations and
emergency department visits in patients with severe COPD. COPD 2007,
4(1):29-39.
26. Atis S, Kanik A, Ozgur ES, Eker S, Tumkaya M, Ozge C: [How exactly can we
predict the prognosis of COPD]. Tuberk Toraks 2009, 57(3):289-297.
27. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R,
Court-Fortune Perez T, Carre P, Roche N: Clinical COPD phenotypes: a
novel approach using principal component and cluster analyses. Eur
Respir J 2010, 36(3):472-4.
28. Bailey WC, Sciurba FC, Hanania NA, Donohue JF, Ferguson GT, Zibrak JD,
Sharafkhaneh A, Marcus P, Rosa K, Piault EC, Martinez FJ: Development and
validation of the Chronic Obstructive Pulmonary Disease Assessment
Questionnaire (COPD-AQ). Prim Care Respir J 2009, 18(3):198-207.
29. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N,
MacNee W, Jones P, Pride N, Rodriguez-Roisin R, Rossi A, Wanner A:
Proposal for a multidimensional staging system for chronic obstructive
pulmonary disease. Respir Med 2005, 99(12):1546-1554.
30. Eisner MD, Trupin L, Katz PP, Yelin EH, Earnest G, Balmes J, Blanc PD:
Development and validation of a survey-based COPD severity score.
Chest 2005, 127(6):1890-1897.
31. Jones P, Harding G, Wiklund I, Berry P, Leidy N: Improving the process and
outcome of care in COPD: development of a standardised assessment
tool. Prim Care Respir J 2009, 18(3):208-215.
32. Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E: Validation
of the COPD severity score for use in primary care: the NEREA study. Eur
Respir J 2009, 33(3):519-527.
33. Peters JB, Daudey L, Heijdra YF, Molema J, Dekhuijzen PN, Vercoulen JH:
Development of a battery of instruments for detailed measurement of
health status in patients with COPD in routine care: the Nijmegen
Clinical Screening Instrument. Qual Life Res 2009, 18(7):901-912.
34. Selim AJ, Ren XS, Fincke G, Rogers W, Lee A, Kazis LA: Symptom-based
measure of the severity of chronic lung disease: results from the
Veterans Health Study. Chest 1997, 111(6):1607-1614.
35. Vercoulen JH, Daudey L, Molema J, Vos PJ, Peters JB, Top M, Folgering H:
An Integral assessment framework of health status in chronic
obstructive pulmonary disease (COPD). Int J Behav Med 2008,
15(4):263-279.
36. Verhage TL, Heijdra YF, Molema J, Daudey L, Dekhuijzen PN, Vercoulen JH:
Adequate Patient Characterization in COPD: Reasons to Go Beyond
GOLD Classification. Open Respir Med J 2009, 3:1-9.
37. Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G: Development
of a COPD severity score. Curr Med Res Opin 2006, 22(9):1679-1687.
38. Yeh ML, Chen HH, Liao YC, Liao WY: Testing the functional status model
in patients with chronic obstructive pulmonary disease. J Adv Nurs 2004,
48(4):342-350.
39. Cote CG, Celli BR: BODE index: a new tool to stage and monitor
progression of chronic obstructive pulmonary disease. Pneumonol Alergol
Pol 2009, 77(3):305-313.
40. Martinez FJ, Han MK, Andrei AC, Wise R, Murray S, Curtis JL, Sternberg A,
Criner G, Gay SE, Reilly J, Make B, Ries AL, Sciurba F, Weinmann G,
Mosenifar Z, DeCamp M, Fishman AP, Celli BR: Longitudinal change in the
BODE index predicts mortality in severe emphysema. Am J Respir Crit
Care Med 2008, 178(5):491-499.
41. Ong KC, Earnest A, Lu SJ: A multidimensional grading system (BODE
index) as predictor of hospitalization for COPD. Chest 2005,
128(6):3810-3816.
42. Howell S, Coory M, Martin J, Duckett S: Using routine inpatient data to
identify patients at risk of hospital readmission. BMC Health Serv Res 2009,
9:96.
43. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA,
Pinto Plata V, Cabral HJ: The Body-Mass Index Airflow Obstruction
Dyspnea and Exercise Capacity Index in Chronic Obstructive Pulmonary
Disease. N Engl J Med 2004, 350(10):1005-1012.
44. Esteban C, Quintana JM, Aburto M, Moraza J, Capelastegui A: A simple
score for assessing stable chronic obstructive pulmonary disease. QJM
2006, 99(11):751-759.
45. American Thoracic Society: Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1995, 152:S77-S120.
46. American Thoracic Society: Lung function testing: selection of reference
values and interpretative strategies. Am Rev Respir Dis 1991,
144:1202-1218.
47. Omachi TA, Yelin EH, Katz PP, Blanc PD, Eisner MD: The COPD severity
score: a dynamic prediction tool for health-care utilization. COPD 2008,
5(6):339-346.
48. Briggs A, Spencer M, Wang H, Mannino D, Sin DD: Development and
validation of a prognostic index for health outcomes in chronic
obstructive pulmonary disease. Arch Intern Med 2008, 168(1):71-79.
49. Kostianev SS, Hodgev VA, Iluchev DH: Multidimensional system for
assessment of COPD patients Comparison with BODE index. Folia Med
(Plovdiv) 2008, 50(4):29-38.
50. Mehrotra N, Freire AX, Bauer DC, Harris TB, Newman AB, Kritchevsky SB,
Meibohm B: Predictors of mortality in elderly subjects with obstructive
airway disease: the PILE score. Ann Epidemiol 2010, 20(3):223-232.
51. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR:
Severe exacerbations and BODE index: two independent risk factors for
death in male COPD patients. Respir Med 2009, 103(5):692-699.
52. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M,
Harding S, Wedzicha JA, Price D, Hyland ME: Derivation and Validation of
a Composite Index of Severity in Chronic Obstructive Pulmonary Disease
- The DOSE Index. Am J Respir Crit Care Med 2009, 180(12):1189-95.
53. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner W, Sharafkhaneh A,
Sarosi GA, Krumpe P, Pieper K, Kesten S: Risk indexes for exacerbations
and hospitalizations due to COPD. Chest 2007, 131:20-28.
54. Azarisman MS, Fauzi MA, Faizal MP, Azami Z, Roslina AM, Roslan H: The
SAFE (SGRQ score air-flow limitation and exercise tolerance) Index: a
new composite score for the stratification of severity in chronic
obstructive pulmonary disease. Postgrad Med J 2007, 83(981):492-497.
55. Cardoso F, Tufanin AT, Colucci M, Nascimento O, Jardim JR: Replacement
of the 6-min walk test with maximal oxygen consumption in the BODE
Index applied to patients with COPD: an equivalency study. Chest 2007,
132(2):477-482.
56. Schembri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D,
MacDonald TM, Winter JH: A predictive model of hospitalisation and
death from chronic obstructive pulmonary disease. Respir Med 2009,
103(10):1461-1467.
57. Gruffydd-Jones K, Richman J, Jones RC, Wang X: A pilot study of
identification and case management of high-risk COPD patients in a
general practice. Fam Pract 2010, 27(5):494-8.
58. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R,
Dallongeville J, de Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C,
Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z,
Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D,
Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A,
Vahanian A, et al: European guidelines on cardiovascular disease
prevention in clinical practice: full text Fourth Joint Task Force of the
European Society of Cardiology and other societies on cardiovascular
disease prevention in clinical practice (constituted by representatives of
nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007,
14(Suppl 2):S1-113.
van Dijk et al. Respiratory Research 2011, 12:151
http://respiratory-research.com/content/12/1/151
Page 10 of 1159. van den Bemt L, Smeele I, van Weel C: Prognostic assessment of patients
with COPD. Lancet 2009, 374(9705):1886-1887.
60. Wildman MJ, Sanderson C, Groves J, Reeves BC, Ayres J, Harrison D,
Young D, Rowan K: Implications of prognostic pessimism in patients with
chronic obstructive pulmonary disease (COPD) or asthma admitted to
intensive care in the UK within the COPD and asthma outcome study
(CAOS): multicentre observational cohort study. BMJ 2007,
335(7630):1132.
61. Siebeling L, ter Riet G, van der Wal WM, Geskus RB, Zoller M,
Muggensturm P, Joleska I, Puhan MA: ICE COLD ERIC–International
collaborative effort on chronic obstructive lung disease: exacerbation
risk index cohorts–study protocol for an international COPD cohort
study. BMC Pulm Med 2009, 9:15.
62. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G,
Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R: Evaluation of
COPD Longitudinally to Identify Predictive Surrogate End-points
(ECLIPSE). Eur Respir J 2008, 31(4):869-873.
63. Esteban C, Quintana JM, Moraza J, Aburto M, Aguirre U,
Aguirregomoscorta JI, Aizpiri S, Basualdo LV, Capelastegui A: BODE-Index vs
HADO-score in chronic obstructive pulmonary disease: Which one to
use in general practice? BMC Med 2010, 8:28.
64. Cote CG, Celli BR: Pulmonary rehabilitation and the BODE index in COPD.
Eur Respir J 2005, 26(4):630-636.
65. Nasis IG, Vogiatzis I, Stratakos G, Athanasopoulos D, Koutsoukou A,
Daskalakis A, Spetsioti S, Evangelodimou A, Roussos C, Zakynthinos S:
Effects of interval-load versus constant-load training on the BODE index
in COPD patients. Respir Med 2009, 103(9):1392-1398.
66. Weston AD, Hood L: Systems biology proteomics and the future of
health care: toward predictive preventative and personalized medicine. J
Proteome Res 2004, 3(2):179-196.
67. Wildman MJ, Sanderson C, Groves J, Reeves BC, Ayres J, Harrison D,
Young D, Rowan K: Predicting mortality for patients with exacerbations
of COPD and Asthma in the COPD and Asthma Outcome Study (CAOS).
QJM 2009, 102(6):389-399.
doi:10.1186/1465-9921-12-151
Cite this article as: van Dijk et al.: Multidimensional prognostic indices
for use in COPD patient care. A systematic review. Respiratory Research
2011 12:151.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van Dijk et al. Respiratory Research 2011, 12:151
http://respiratory-research.com/content/12/1/151
Page 11 of 11